JANX Stock Summary and Trading Ideas (Janux Therapeutics | NASDAQ:JANX)

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Janux Therapeutics trades on the NASDAQ stock market under the symbol JANX.

As of January 29, 2026, JANX stock price declined to $13.83 with 852,088 million shares trading.

JANX has a beta of 1.17, meaning it tends to be more sensitive to market movements. JANX has a correlation of 0.05 to the broad based SPY ETF.

JANX has a market cap of $831.10 million. This is considered a Small Cap stock.

Last quarter Janux Therapeutics reported $10 million in Revenue and -$.39 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.22.

In the last 3 years, JANX traded as high as $71.71 and as low as $5.65.

The top ETF exchange traded funds that JANX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.

JANX has underperformed the market in the last year with a price return of -67.0% while the SPY ETF gained +16.0%. JANX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -53.5% and -2.1%, respectively, while the SPY returned +1.3% and +0.5%, respectively.

JANX support price is $13.48 and resistance is $14.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JANX shares will trade within this expected range on the day.